SCHEDULE 13D/A
0000918923
XXXXXXXX
LIVE
2
Common Shares
10/09/2025
true
0001633932
29668H708
ESSA Pharma Inc.
SUITE 720
999 WEST BROADWAY
VANCOUVER, BRITISH COLUMBIA
A1
V5Z 1G8
JAMES KRATKY
415-525-8800
BVF PARTNERS L.P.
44 Montgomery St., 40th Floor
San Francisco
CA
94104
KENNETH A. SCHLESINGER, ESQ.
212-451-2300
OLSHAN FROME WOLOSKY LLP
1325 Avenue of the Americas
New York
NY
10019
0000918923
N
BIOTECHNOLOGY VALUE FUND L P
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
PN
0001803805
N
BVF I GP LLC
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
OO
0001102444
N
BIOTECHNOLOGY VALUE FUND II LP
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
PN
0001803806
N
BVF II GP LLC
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
OO
0001660683
N
Biotechnology Value Trading Fund OS LP
a
N
E9
0.00
0.00
0.00
0.00
0.00
N
0
PN
0001660684
N
BVF Partners OS Ltd.
a
N
E9
0.00
0.00
0.00
0.00
0.00
N
0
CO
0001803809
N
BVF GP HOLDINGS LLC
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
OO
0001055947
N
BVF PARTNERS L P/IL
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
IA
PN
0001056807
N
BVF INC/IL
a
N
DE
0.00
0.00
0.00
0.00
0.00
N
0
CO
0001233840
N
LAMPERT MARK N
a
N
X1
0.00
0.00
0.00
0.00
0.00
N
0
IN
Common Shares
ESSA Pharma Inc.
Item 3 is hereby amended and restated to read as follows:
As described in Items 4 and 5 below, the Reporting Persons no longer beneficially own any Shares.
Item 4 is hereby amended to add the following:
Effective October 9, 2025, the Issuer was acquired by Xeno Acquisition Corp. (the "Purchaser") pursuant to an arrangement under Section 288 of the Business Corporations Act (British Columbia) involving the Issuer, XenoTherapeutics, Inc. (the "Parent"), Purchaser, a wholly-owned subsidiary of Parent, and XOMA Royalty Corporation pursuant to a business combination agreement dated July 13, 2025 and the plan of arrangement, pursuant to which, among other things, the Purchaser acquired all of the outstanding Shares in exchange for: (i) $0.124231 in cash per Share (excluding the approximately $1.69 of cash per Share previously distributed to the Issuer's shareholders) and (ii) one contingent value right per Share for potential cash payments of up to approximately $0.14 per Share.
Accordingly, the Reporting Persons ceased to beneficially own any securities of the Issuer.
Item 5(a) is hereby amended and restated to read as follows:
As described in Item 4 above, the Reporting Persons no longer beneficially own any Shares
Item 5(c) is hereby amended and restated to read as follows:
Except as set forth in Item 4 above, the Reporting Persons have not entered into any transactions in the securities of the Issuer during the past 60 days.
Item 5(e) is hereby amended and restated to read as follows:
As of October 9, 2025, the Reporting Persons ceased to be the beneficial owners of more than 5% of the outstanding Shares.
BIOTECHNOLOGY VALUE FUND L P
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF I GP LLC
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BIOTECHNOLOGY VALUE FUND II LP
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF II GP LLC
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
Biotechnology Value Trading Fund OS LP
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF Partners OS Ltd.
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF GP HOLDINGS LLC
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF PARTNERS L P/IL
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
BVF INC/IL
/s/ Mark N. Lampert
Mark N. Lampert, Authorized Signatory
10/14/2025
LAMPERT MARK N
/s/ Mark N. Lampert
Mark N. Lampert
10/14/2025